An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Diabetes is a major risk factor for the development of stroke. Glucagon-like peptide-1 receptor (GLP-1R) agonists have been in clinical use for the treatment of diabetes and also been reported to be neuroprotective in ischemic stroke. The quinoxaline 6,7-dichloro-2-methylsulfonyl-3-N-tert- butylaminoquinoxaline (DMB) is an agonist and allosteric modulator of the GLP-1R with the potential to increase the affinity of GLP-1 for its receptor. The aim of this study was to evaluate the neuroprotective effects of DMB on transient focal cerebral ischemia. In cultured cortical neurons, DMB activated the GLP-1R, leading to increased intracellular cAMP levels with an EC50 value about 100 fold that of exendin-4. Pretreatment of neurons with DMB protected against necrotic and apoptotic cell death was induced by oxygen-glucose deprivation (OGD). The neuroprotective effects of DMB were blocked by GLP-1R knockdown with shRNA but not by GLP-1R antagonism. In C57BL/6 mice, DMB was orally administered 30 min prior to middle cerebral artery occlusion (MCAO) surgery. DMB markedly reduced the cerebral infarct size and neurological deficits caused by MCAO and reperfusion. The neuroprotective effects were mediated by activation of the GLP-1R through the cAMP-PKA-CREB signaling pathway. DMB exhibited anti-apoptotic effects by modulating Bcl-2 family members. These results provide evidence that DMB, a small molecular GLP-1R agonist, attenuates transient focal cerebral ischemia injury and inhibits neuronal apoptosis induced by MCAO. Taken together, these data suggest that DMB is a potential neuroprotective agent against cerebral ischemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Specifically, activation of GLP-1R leads to an increase in cAMP levels, which in turn activates PKA, a widely regulating enzyme of cellular functions, capable of phosphorylating a variety of target proteins, thereby initiating the PKA/CREB signaling pathway.326,327”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [326]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182456d46 · Cited by 1,512
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2014) · Circulation · doi:10.1161/01.cir.0000442015.53336.12 · Cited by 1,408 · cited 1×
“Ischemic stroke is a leading cause of adult morbidity and mortality worldwide with very limited treatment options [1].”
BackgroundBederson, J. B., Pitts, L. H., Germano, S. M., Nishimura, M. C., Davis, R. L., & Bartkowski, H. M. (1986) · Stroke · doi:10.1161/01.str.17.6.1304 · Cited by 1,277 · cited 1×
“After evaluation of neurological deficits, the infarct volume was measured by TTC staining, which has been widely used for accurately reflecting the extent of irreversible ischemic damage in cerebral tissues [20].”
MethodKieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062 · cited 1×
“Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide secreted from the L-cells of the small intestine [2].”
BackgroundThorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906 · cited 1×
“GLP-1 exerts its effects by binding to GLP-1 receptor (GLP-1R), a member of the class B family of seven transmembrane G protein-coupled receptors (GPCRs) [3].”
BackgroundDeacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837 · cited 1×
“To further evaluate the mechanism, we exposed the cells to exendin (9–39) (1 μM), an orthosteric competitive antagonist [23, 24].”
BackgroundLi, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 1×
“found that intracerebral administration of exendin-4 induced neuroprotection and locomotor activity after stroke in the rat, and showed this neuroprotective effect was mediated by GLP-1R in GLP-1R knockout mice [4].”
Background
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Salameh, T. S., Rhea, E. M., Talbot, K., & Banks, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114187 · Cited by 188
“Our findings are relevant beyond AD and PD, because systemically administered IRAs also show promise in treating other neurological conditions, most notably amyotrophic lateral sclerosis (ALS) [133, 134], stroke [100, 135-140], and traumatic brain injury (TBI) [141].”
BackgroundGLP-1’s role in neuroprotection: a systematic review
Erbil, D., Eren, C. Y., Demirel, C., Küçüker, M. U., Solaroğlu, I., & Eser, H. Y. (2019) · Brain Injury · doi:10.1080/02699052.2019.1587000 · Cited by 126
“3 levels (131,154), decreasing inflammatory factors (147), altering cAMP-PKA-CREB signaling (128,129,131,154), inhibiting oxidative stress (129,134,135), increasing BDNF (144) and VEGF (146), increasing healthy and proliferating cell numbers (133,143) and microvessel density (136) (Table 4a).”
BackgroundSmall-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity
Fontana, P., Du, G., Zhang, Y., Zhang, H., Vora, S. M., Hu, J. J., Shi, M., Tufan, A. B., Healy, L. B., Xia, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.08.007 · Cited by 139
Self-citationProtective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions
Bhalla, S., Mehan, S., Khan, A., & Rehman, M. U. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104896 · Cited by 108
Duarte, A. I., Candeias, E., Alves, I. N., Mena, D., Silva, D. F., Machado, N. J., Campos, E. J., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051746 · Cited by 90
Yang, J.-L., Chen, W.-Y., Chen, Y.-P., Kuo, C.-Y., & Chen, S.-D. (2016) · Theranostics · doi:10.7150/thno.15993 · Cited by 74
“Many studies have revealed that GLP-1[32,44], EX-4 [45-47], and other agonists of GLP-1R [40,48] have a neuroprotective role against neurodegenerative cell death, traumatic brain injury, and ischemic stroke.”
BackgroundMarlet, I. R., Ölmestig, J. N. E., Vilsbøll, T., Rungby, J., & Kruuse, C. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12974 · Cited by 61
Yang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844697 · Cited by 58
“In this study, similar results were obtained where the neuroprotection of DMB was inhibited by the knockdown of GLP-1 receptor with shRNA but not by a GLP-1 receptor antagonist, and the cAMP induced by DMB was not suppressed by Ex 9-39 (121).”
BackgroundResultNeprilysin inhibitors and risk of Alzheimer's disease: A future perspective
Ali, N. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alnaaim, S. A., Alexiou, A. T., Papadakis, M., Khalifa, A. A., Saad, H. M., & Batiha, G. E. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17993 · Cited by 61
“88 Experimental studies confirmed that GLP-1 and GLP-1 analogues attenuate A β accumulation, tau protein phosphorylation, neurotoxicity and neuroinflammation.”
BackgroundWang, R.-F., Xue, G., Hölscher, C., Tian, M.-J., Feng, P., Zheng, J.-Y., & Li, D. (2018) · Epilepsy Research · doi:10.1016/j.eplepsyres.2018.03.009 · Cited by 58
“We and others have shown that activation of the GLP-1 receptor can reverse the mitochondrial stress signalling induced by toxins and increase Bcl-2 levels and decrease BAX levels [57-60].”
BackgroundMaskery, M. P., Holscher, C., Jones, S. P., Price, C. I., Strain, W. D., Watkins, C. L., Werring, D. J., & Emsley, H. C. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20952011 · Cited by 51
Rachmany, L., Tweedie, D., Rubovitch, V., Li, Y., Holloway, H. W., Kim, D. S., Ratliff, W. A., Saykally, J. N., Citron, B. A., Hoffer, B. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-03792-9 · Cited by 47
Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury
Glotfelty, E. J., Delgado, T. E., Tovar-y-Romo, L. B., Luo, Y., Hoffer, B. J., Olson, L., Karlsson, T. E., Mattson, M. P., Harvey, B. K., Tweedie, D., et al. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00003 · Cited by 48
Darsalia, V., Klein, T., Nyström, T., & Patrone, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.022 · Cited by 43
Malik, F., & Li, Z. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15446 · Cited by 41
Insulin in the Management of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Cerecedo-Lopez, C. D., Cantu-Aldana, A., Patel, N. J., Aziz-Sultan, M. A., Frerichs, K. U., & Du, R. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.01.056 · Cited by 40
Huang, J., Liu, Y., Cheng, L., Li, J., Zhang, T., Zhao, G., & Zhang, H. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173581 · Cited by 36
Self-citationWolak, M., Staszewska, T., Juszczak, M., Gałdyszyńska, M., & Bojanowska, E. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.10.053 · Cited by 37
Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes
Bonnet, F., & Scheen, A. J. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.04.004 · Cited by 38
Li, Q., Li, Z., Fan, Z., Yang, Y., & Lu, C. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4875 · Cited by 35
“It has been identified as a vital physiological regulator of insulin secretion and a major therapeutic target for the treatment of ischemic stroke and diabetes (51,52).”
BackgroundRathmann, W., & Kostev, K. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01943-7 · Cited by 32
“Therefore, the GLP-1 receptor is a promising therapeutic target for central nervous system diseases including stroke [16].”
BackgroundInfluentialChen, Y., Zhang, X., He, J., Xie, Y., & Yang, Y. (2018) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2017.12.015 · Cited by 32
Inhibiting Jumoji domain containing protein 3 (JMJD3) prevent neuronal apoptosis from stroke
Zhang, H., Wang, J., Huang, J., Shi, T., Ma, X., Luo, X., Li, X., & Li, M. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.07.007 · Cited by 30
“The MCAO procedure was conducted as previously described (Zhang et al., 2016b).”
Self-citationLi, C., Li, J., Xu, G., & Sun, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-63213-2 · Cited by 29
Olukorode, J., Orimoloye, D. A., Nwachukwu, N. O., ONWUZO, C. N., Oloyede, P. O., Fayemi, T., Odunaike, O. S., Ayobami-Ojo, P. S., Divine, N., Alo, D. J., et al. (2024) · Cureus · doi:10.7759/cureus.72080 · Cited by 42
Wang, J., Zhang, W., Lv, C., Wang, Y., Ma, B., Zhang, H., Fan, Z., Li, M., & Li, X. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107918 · Cited by 27
Self-citationThe Emerging Role of GLP-1 Receptors in DNA Repair: Implications in Neurological Disorders
Yang, J., Chen, W., & Chen, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091861 · Cited by 25
“Two studies in the cerebral ischemic rat model reported that EX-4 exerted neuroprotective functions through AKT-eNOS and cAMP-PKA-CREB, respectively [113,114].”
BackgroundSchubert, M., Stichel, J., Du, Y., Tough, I. R., Sliwoski, G. R., Meiler, J., Cox, H. M., Weaver, C. D., & Beck‐Sickinger, A. G. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00976 · Cited by 25
Upregulation of TRPC1 in microglia promotes neutrophil infiltration after ischemic stroke
Qian, H., Zhang, H., Gao, T. X., Wang, X., Wang, X., Yu, M.-Y., Li, M., & Huang, J. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.110894 · Cited by 23
Self-citationWu, P., Zhao, Y., Zhuang, X., Sun, A., Zhang, Y., & Ni, Y. (2018) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2018.08.012 · Cited by 24
Šmelcerović, A., Lazarević, J., Tomović, K., Anastasijevic, M., Jukič, M., Kocic, G. M., & Anderluh, M. (2019) · ChemMedChem · doi:10.1002/cmdc.201800699 · Cited by 20
Huang, J., Wang, X., Gao, T. X., Wang, X., Yu, M.-Y., Song, H., Wang, B.-Y., Li, L., Zeng, Q., & Zhang, H. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231216158 · Cited by 20
Self-citationPoupon-Bejuit, L., Rocha‐Ferreira, E., Thornton, C., Hagberg, H., & Rahim, A. A. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00112 · Cited by 17
Exendin-4 induces a novel extended effect of ischemic tolerance via crosstalk with IGF-1R
Zhang, H., Liu, Y., Cheng, L., Ma, X., & Luo, X. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.11.008 · Cited by 16
Self-citationTu, X.-K., Chen, P., Chen, J., Ding, Y.-H., Chen, Q., & Shi, S. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109603 · Cited by 14
From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists
Dave, B. P., Chorawala, M. R., Shah, I., Shah, N. N., Bhagat, S. U., Prajapati, B. G., & Thakkar, P. C. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09793-y · Cited by 17
The role of the GLP-1/GLP-1R signaling pathway in regulating seizure susceptibility in rats
Zhang, Y., Fang, J., Feng, W., Sun, Q., Xu, J., & Xia, Q. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.06.017 · Cited by 14
Michaelsen, M. K., Drasbek, K. R., Valentin, J. B., Svart, M. V., Larsen, J. B., Kruuse, C. R., Simonsen, C. Z., & Blauenfeldt, R. A. (2025) · Stroke · doi:10.1161/strokeaha.125.053075 · Cited by 15
Zhang, T., Ruan, H.-Z., Wang, Y., Shao, Y., Zhou, W., Weng, S.-J., & Zhong, Y. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00826-9 · Cited by 11
Poupon-Bejuit, L., Geard, A. F., Millicheap, N., Rocha‐Ferreira, E., Hagberg, H., Thornton, C., & Rahim, A. A. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00079-1 · Cited by 8
“…of other studies showing that GLP1-R agonists attenuate neuronal death via the GLP1-R/PI3K/Akt pathway in various models of neurodegeneration (Chen et al, 2016; Xie et al, 2018; Zhang et al, 2016; Zhu et al, 2016) and more recently in a study in neonatal rats with HI injury (Zeng et al, 2019).”
InfluentialA quinoxaline-based compound ameliorates bone loss in ovariectomized mice
Zhou, Y. J., Xue, X., Guo, Y., Liu, H., Hou, Z., Zhou, C., Wang, N., Li, F., & Wang, Y. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211032133 · Cited by 10
Self-citationYoon, J. P., Park, S.-J., Kim, D.-H., Choi, Y., Lee, H., Kim, J.-Y., Cho, C., & Chung, S. W. (2025) · The American Journal of Sports Medicine · doi:10.1177/03635465251369517 · Cited by 7
“11,42 Activation of this pathway enhances the expression of BDNF, a neurotrophic factor that promotes energy metabolism and muscle regeneration, ultimately leading to the maintenance of muscle health, preservation of muscle strength, and suppression of FI.”
The role of GLP-1 receptor in pain disorders and its pharmacological properties
Jing, F., Zeng, Y., Yu, Q.-L., & Fu, C. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178345 · Cited by 6
Samanidou, V., Tsamis, K., Ceasovschih, A., Koufakis, T., Patoulias, D., Rizos, E. C., Rizzo, M., Milionis, H. J., & Barkas, F. (2026) · Journal of Central Nervous System Disease · doi:10.1177/11795735261444425 · Cited by 4
GLP-1 Receptor Agonists: Beyond Diabetes—What the Neurosurgeon Needs to Know
Abdulrazeq, H., Taman, M., Ali, R., Doberstein, C., Sullivan, P. Z., Sampath, P., Telfeian, A. E., Gokaslan, Z. L., Fridley, J., & Asaad, W. F. (2024) · Neurosurgery Open · doi:10.1227/neuprac.0000000000000098 · Cited by 7
Chen, H. A., McIntyre, M. K., Kakadiya, J., Rai, P., Essibayi, M. A., Salim, H. A., Azzam, A. Y., Latifikhereshky, S., Yedavalli, V. S., Altschul, D., et al. (2026) · Stroke · doi:10.1161/strokeaha.126.055692 · Cited by 3
Barks, A. K., Beeson, M. M., Matveeva, T. M., Gale, J. J., Rao, R., & Tran, P. V. (2018) · Developmental Neuroscience · doi:10.1159/000499126 · Cited by 2
Candeias, E. M. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
Exendin-4 as a multi-target therapy for Fetal Inflammatory Response Syndrome-induced brain injury
Li, S., Cai, C., & Arigong, G. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1848474
“…promotes the generation of new, healthy mitochondria through the activation of the PGC-1 α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) signaling axis, thereby providing the essential energy supply required for the recovery and proper function of injured neural cells (36).”
BindingDB Entry 50000119: Identification and Characterization of the First Selective Y
BindingDB (2019) · UC San Diego · doi:10.7270/q22b915r
Metadata
- Authors
- Zhang, H., Liu, Y., Guan, S., Qu, D., Wang, L., Wang, X., Li, X., Zhou, S., Zhou, Y., Wang, N., Meng, J., & Ma, X.
- Affiliations
- Air Force Medical University (CN)
- Corresponding author
- Meng, Jingru
- Ma, Xue
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-02-10
- Volume
- 11
- Issue
- 2
- Pages
- e0148827
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4749391
- OpenAlex
- W2265017848
- Cited by
- 50
- References
- 44
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 7 · 2023: 3 · 2022: 4 · 2021: 3 · 2020: 8 · 2019: 4 · 2018: 8 · 2017: 5 · 2016: 1
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81402931, 81471093, 81571278)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor, allosteric agonists, DMB, neuroprotection, cerebral ischemia, ischemic stroke, middle cerebral artery occlusion, oxygen-glucose deprivation, neuronal apoptosis, cAMP/PKA/CREB signaling, Bcl-2 family proteins, oral administration, diabetes mellitus
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Allosteric Regulation, Animals, Blood Glucose, Brain, Cell Survival, Cells, Cultured, Drug Evaluation, Preclinical, Insulin, Male, Mice, Inbred C57BL, Neurons, Peptides, Quinoxalines, Sulfones, Venoms, Reperfusion Injury, Apoptosis, Neuroprotective Agents, Inhibitory Concentration 50, Infarction, Middle Cerebral Artery, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.